Recipharm was established in Sweden in 1995 and has since then grown to become a leading Contract Development and Manufacturing Organisation (CDMO) and is headquartered close to Stockholm.
Today, Recipharm operates 25 facilities in 10 countries (France, Germany, India, Italy, Israel, Portugal, Spain, Sweden, USA and the UK) covering most of the pharmaceutical dosage forms. Recipharm employs around 4.000 people and is listed on NASDAQ Stockholm.
In October 2014 Recipharm acquired Italian Corvette Group including all the operating companies based in Milan (Biologici Italia Laboratories, Edmond Pharma, Liosintex).
In February 2016 Mitim, located in Brescia, was acquired.
In Italy Recipharm operates four manufacturing facilities, specialized in parenterals of freeze-dried and liquid vials and ampoules, lyophilisation of sterile beta-lactam antibiotics in bulk, filling of beta-lactams powder, APIs synthesis oral solid form, Erdosteine business (API synthesis and finished dosages).
Recipharm has the competence, flexibility and facilities to take on challenging projects which require custom tailored processes. With a broad range of expertise and technologies available, Recipharm offers support and services ranging from development and procurement to full-scale manufacturing, distribution, technology transfer and stability studies. In addition to human pharmaceuticals, Recipharm can also supply medical devices and veterinary products.
Please visit our web site: www.recipharm.com
A roundup of some of the biggest stories from Italian pharma and healthcare, including Italfarmaco’s FDA approval for its DMD treatment; Alfasigma’s acquisition of Galapagos’s Jyseleca, the antibiotics deal between…
The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic…
After former CEO Pierluigi Antonelli abruptly announced his departure last month, the Italian mid-cap has signed on former Gilead leader, Jacopo Andreose, as its new chief executive. [I am]…
Angelini Pharma CEO Pierluigi Antonelli has announced that he is leaving his position with immediate effect, posing the question of what comes next for the leading Italian mid-cap. Antonelli,…
The electoral victory of the centre-right coalition in Italy should see far-right firebrand Giorgia Meloni replace former European Central Bank President Mario Draghi as Prime Minister at the end of…
Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in…
The Italian system requires drug companies to go through approvals at a national level with the Italian Medicines Agency (AIFA), only to then confront the country’s 21 regional authorities who…
Historically, SIFI has been a modest local player focused on ophthalmic products, but in recent years the company has set some ambitious goals for itself—becoming a leading force in European…
Seasoned executive Pierluigi Antonelli went from a career in big pharma to Angelini Pharma, a midsized Italian company that has been undergoing major transformation. He shares the motivation behind the…
Collectively representing almost 400 companies operating in Italy, Farmindustria, Egualia (formerly Assogenerici) and Assobiotec respectively promote the interests of innovative pharmaceutical companies—both foreign and Italian-owned— the generics, biosimilars and value-added…
As the European Union’s largest beneficiary of the Next Generation EU (NGEU) package, aimed at boosting the EU’s economy following the COVID-19 pandemic, Italy will receive some EUR 235 billion…
While Italy’s biotech landscape is generally held to be somewhat immature in comparison to more established markets such as Germany, France or the UK, that does not imply a deficit…
See our Cookie Privacy Policy Here
